#USA #New York #Faruqi & Faruqi #Applied Therapeutics #Josh Wilson

APLT Investor Alert: Legal Rights for Affected Investors

In light of recent revelations about Applied Therapeutics, Inc., leading national securities law firm, Faruqi & Faruqi, LLP, is reaching out to investors who suffered financial losses exceeding $50,000 as a result of trading its stocks. Investors are encouraged to contact James (Josh) Wilson, a partner at the firm, to discuss their legal options.

Background of the Case

The firm is investigating claims related to potential violations of federal securities laws by Applied Therapeutics (NASDAQ: APLT). This investigation comes in the wake of significant stock price drops following adverse announcements regarding the company's clinical trials. Specifically, the firm's complaint highlights misleading statements made by the company and its executives concerning the status of their pivotal Phase III INSPIRE trial.

According to the allegations, Applied Therapeutics provided misleading information while failing to disclose crucial facts regarding dosing errors and electronic data capture issues that took place during the trial. These misleading statements led investors to purchase shares at artificially inflated prices, ultimately resulting in substantial financial losses when the stock price plummeted.

Key Developments

• - On November 27, 2024, Applied Therapeutics announced the U.S. FDA issued a Complete Response Letter (CRL) for their New Drug Application concerning govorestat, an aldose reductase inhibitor aimed at treating Classic Galactosemia. The inability to approve the application in its current form due to identified issues triggered a sharp decline in stock prices, leading to a close at $8.57, a 16.06% drop.

• - Further compounding losses, on December 3, 2024, the FDA released a Warning Letter highlighting that the company had known about major issues with the govorestat NDA as early as May 2024, which resulted in a further decline to $1.38 per share, representing an additional drop of 18.34% in just one day.

Call to Action for Investors

Faruqi & Faruqi informs potential claimants that the deadline to apply for the role of lead plaintiff in the federal securities class action against Applied Therapeutics is February 18, 2025. An investor seeking this role would typically be one who possesses the largest financial interest in the claimed relief and demonstrates adequacy in representing class members. This opportunity allows investors to direct and oversee the litigation regarding their grievances effectively.

Should you wish to assert your rights or explore legal avenues, including joining the class action or acting as a lead plaintiff, do not hesitate to contact Josh Wilson directly by calling 877-247-4292 or 212-983-9330 (Ext. 1310).

Encouragement for Whistleblowers and Employees

Faruqi & Faruqi not only invites affected investors but also seeks information from whistleblowers, former employees, or any individual aware of relevant conduct by Applied Therapeutics. Reporting such insider knowledge could play a vital role in the ongoing investigation.

To stay updated on this matter and receive support, you can visit their website at www.faruqilaw.com/APLT. Remember, all inquiries will be treated with the utmost confidentiality.

As this situation unfolds, it highlights the importance of transparency and integrity in the securities market, reminding investors to stay vigilant and proactive in safeguarding their investments.